Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
The future of the cannabis industry is looking bright. Tilray (NASDAQ: TLRY) is representative of many of the problems and risks of cannabis investing. Between its consistently high operating costs, poor revenue growth, and weak stock performance, investing in it would be a bold bet on a turnaround.
Fastly (NYSE: FSLY), Moderna (NASDAQ: MRNA), and Tilray (NASDAQ: TLRY) are three stocks that have been on a tear for much of November. Indeed, shares of the cloud computing service provider, the coronavirus vaccine drugmaker, and the medical marijuana company are up close to 23%, 110%, and 52% over the month, respectively. Fastly stock has taken a beating this year.